Diagnostic Approach to Erythrocytosis in Patients Awaiting Sleep‑Apnea Evaluation

1. Definition and Confirmation of Erythrocytosis

• Erythrocytosis is diagnosed when hemoglobin ≥ 18.5 g/dL in men or ≥ 16.5 g/dL in women, or when hematocrit exceeds the 99th percentile for age, sex and altitude, or when erythrocyte mass is > 25 % above the predicted normal value【1】.
• The diagnosis should be confirmed on at least two separate blood draws to exclude transient hemoconcentration【2】.

2. First‑Line Molecular and Hormonal Tests (priority before sleep‑apnea testing)

• JAK2 mutation analysis:
  
  • The JAK2 V617F mutation is present in ≈ 95 % of polycythemia vera (PV) cases【3】.
  • If JAK2 V617F is negative, testing for JAK2 exon 12 mutations is recommended【3】.
• Serum erythropoietin (EPO) measurement:
  
  • Low or suppressed EPO suggests a primary (clonal) erythrocytosis such as PV.
  • Normal or elevated EPO points toward secondary causes (e.g., chronic hypoxia, sleep‑apnea)【4】.

3. Bone‑Marrow Evaluation (when indicated)

• Perform a bone‑marrow biopsy if JAK2 mutation is detected or if serum EPO is low, to look for hypercellularity with pan‑myelosis, which is a minor diagnostic criterion for PV【5】【6】.
• Confirmation of PV by biopsy is advised after a JAK2‑positive + low‑EPO result【1】.

4. Assessment for Secondary Causes of Erythrocytosis

• Chronic hypoxia screening: arterial oxygen saturation < 92 % (or equivalent arterial blood‑gas findings) indicates chronic hypoxemia as a secondary driver【1】.
• Renal evaluation (e.g., serum creatinine, renal imaging) to detect EPO‑producing renal tumors【1】.
• Genetic testing for congenital erythrocytosis when the clinical picture suggests a hereditary form (young age, family history): includes EPO‑receptor mutations and VHL gene mutations【1】.

5. Interaction with Sleep‑Apnea

• Sleep‑apnea does not rule out PV; the two conditions can coexist. In one series, 18 % of erythrocytosis cases were PV, while 29 % of patients with sleep‑apnea had concurrent PV【1】.

6. Impact of Iron Deficiency

• Iron deficiency can mask PV by lowering hemoglobin below diagnostic thresholds; re‑assessment after iron repletion is required when clinical suspicion remains high【5】【6】【2】.

7. Prognostic Implications of Untreated Polycythemia Vera

• Arterial thrombotic events occur in ~16 % of patients at the time of PV diagnosis【2】.
• Progression to acute leukemia is reported in ~6.8 % of PV patients【1】.

All statements are supported by the cited references indicated in brackets.

JAK2 Mutation Testing in Polycythemia Vera

First‑line Molecular Testing

• In patients with suspected polycythemia vera, the initial molecular assay should be a JAK2V617F mutation test performed on peripheral blood (or bone marrow if needed), because this mutation is present in roughly 95 % of polycythemia vera cases and the test is minimally invasive. 7

Testing When JAK2V617F Is Negative

• For individuals in whom the JAK2V617F assay is negative but clinical suspicion for polycythemia vera remains high, JAK2 exon 12 mutation analysis should be performed immediately; exon 12 mutations account for the remaining ~5 % of polycythemia vera cases that are JAK2V617F‑negative. [7][8]9

Bone Marrow Biopsy Decision‑Making

• A bone‑marrow biopsy is not required in patients who are JAK2V617F‑positive and have hemoglobin levels exceeding 18.5 g/dL in men or 16.5 g/dL in women, as these laboratory thresholds together with the mutation provide sufficient diagnostic certainty. 7

JAK2 V617F Mutation Testing for Polycythemia Vera

Epidemiology and Diagnostic Utility

• In patients presenting with erythrocytosis, the JAK2 V617F mutation is detected in approximately 95 % of cases of polycythemia vera, making it the primary molecular assay for confirming the disease. National Comprehensive Cancer Network (NCCN) guidelines endorse this prevalence data. 10

Guideline Recommendations

• A positive JAK2 V617F result, when accompanied by elevated hemoglobin/hematocrit levels, fulfills the NCCN diagnostic criteria for polycythemia vera, allowing a definitive diagnosis without the need for bone‑marrow biopsy. NCCN assigns this recommendation a level of evidence that is not explicitly specified in the source. 10